For 30 years, the Clinique l’Actuel, under the medical direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.
COMPLEX HIV CASES: MULTI-DRUG RESISTANCE AND AUTOIMMUNE DISEASES
With Dr. Réjean Thomas and Dr. Jean-Pierre Routy
After clicking PLAY, click on the lower bar’s subtitles icons for english subtitles.
- Better understanding the principles of resistance to ARV treatments
- Autoimmune diseases and HIV: interactions between treatments
- HIV: collegial intervention
- HIV: importance of knowing the patient’s history
This activity is supported
by an educational grant from:
resistance and HIV
Dr. Jean-Pierre Routy and Dr. Réjean Thomas present two complex cases of HIV that is resistant to multiple drug classes.
Although many people living with HIV respond very well to ARV treatments, they can be problematic for some patients, especially those who have autoimmune diseases. A better understanding of what determines immune tolerance and the role of ARV treatment in HIV autoimmunity will help in adapting treatments for autoimmunity and controlling interactions with ARV treatments.
Resistance to ARV drugs is also a problem for people living with HIV. As new and increasingly effective molecules are discovered to fight HIV, treatments have evolved from monotherapy with AZT to various combinations. In some cases, this succession of drugs may result in the buildup of resistance to a drug or class of drugs, which may limit treatment options.
In conclusion, while HIV treatment options appear to be getting simpler, particularly with single-pill treatments, HIV infection can result in multiple complications. The patient’s entire history must be known and treatment decisions made in a collegial way, with all members of the team of health care professionals.
Réjean Thomas, MD, Dhc
Clinique médicale l’Actuel: Centre of Excellence HIV–STI–Hepatitis
Affiliated with the Centre hospitalier de l’Université de Montréal (CHUM)
Jean-Pierre Routy, M.D. FRCPC
Division of Hematology and Chronic Viral Illness Service
McGill University Health Centre
Incumbent – Louis Lowenstein Chair in Hematology & Oncology
Professor of Medicine
McGill University, Montréal, Québec
AND THE SUPPORT OF
Réjean Thomas, MD, Dhc has a financial interest/relationship or affiliation with:
Advisory Boards: AbbVie, Bristol-Myers Squibb Janssen, Gilead, Merck, ViiV Healthcare
Jean-Pierre Routy, MD, FRCPC has a financial interest/relationship or affiliation with:
Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.